

CURRICULUM VITAE

Barry Ross Meisenberg, M.D., F.A.C.P.

Medical Director DeCesaris Cancer Institute Anne Arundel Medical Center Annapolis MD, 21401	Sep. 2008-present
Medical Director Infusion Service Anne Arundel Medical Center	Sep. 2008-present
Chair for Quality and Health Systems Research Director Center for Health Care Improvement and Health System Research. Anne Arundel Health System Annapolis MD	September 2012-
Visiting Professor of Oncology (part time) Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins University Sep 1, 2008-present	Sep, 2008-present
Interim Director. Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins Bayview Medical Center Chair, Dept. of Oncology, Johns Hopkins Bayview Medical Center	January 2010-March 2012
Professor of Medicine University of Maryland School of Medicine	1998-2008
Head, Division of Hematology/Oncology University of Maryland Department of Medicine University of Maryland School of Medicine Baltimore, Maryland	1998 - 2008
Deputy Director for Clinical Affairs Univ of Maryland Cancer Center	2996-2006

Business Address: 2001 Medical Parkway
Annapolis MD 21401
443-481-5824
Fax 443 481-5890
Meisenberg@AAHS.org
BMeisen1@JHMI.edu

Education and Training

B.S., Biochemistry, State University of New York, Stony Brook, New York <i>Magna cum Laude</i>	1978
M.D., Albany Medical College, Albany, New York	1982

Post Graduate Education

Intern in Categorical Medicine Naval Hospital San Diego, California	1982 – 1983
Residency in Internal Medicine Naval Hospital San Diego, California	1984 – 1986
Fellowship in Hematology/Oncology Naval Hospital San Diego, California	1986 – 1989
Visiting Fellow : Acute Leukemia Service and Bone Marrow Transplant Unit Memorial Sloan-Kettering Cancer Center New York, New York	1988 – 1989

Other Medical Courses

Advanced Trauma Life Support Certification, Combat Casualty Care	1983
Advanced Cardiac Life Support Instructor	1986
Chemical Warfare Casualty Provider Course	1991

Major Academic Tasks and Leadership Roles

Chair for Quality and Health Systems Research Anne Arundel Medical Center	2012-present
Designated Institutional Official for Graduate Medical Education, Anne Arundel Medical Center	2015-present
Executive Committee, Johns Hopkins Clinical Research Network	2009-present
Chief Of Oncology, Johns Hopkins Bayview Medical Center	20010-2012
Head, Division of Hematology and Oncology University of Maryland School of Medicine Baltimore, Maryland	1998-2008

Associate Director for Clinical Research University of Maryland Greenebaum Cancer Center Baltimore, Maryland	2002 - 2004
Clinical Head, Experimental Therapeutics Program University of Maryland Greenebaum Cancer Center Baltimore, Maryland	2003 – 2004
Deputy Director, Clinical Affairs University of Maryland Marlene & Stewart Greenebaum Cancer Center Baltimore, Maryland	1996 - 2006
Medical Director, Cell Therapy/Graft Engineering Apheresis Laboratories University of Maryland Marlene & Stewart Greenebaum Cancer Center Baltimore, Maryland	2002 -2008
Director, Radiation & Combat Injury Department Combat Casualty Care Directorate Naval Medical Research Center Silver Spring, Maryland	April 2002- 2006
Interim Director, Blood and Marrow Transplant Program University of Maryland Greenebaum Cancer Center Baltimore, Maryland	January 2000 - September 2000
Director, Bone Marrow Transplantation Program Scripps Clinic and Research Foundation La Jolla, California	1993 - 1996
Director, Stem Cell Cryopreservation Laboratory Green Hospital of Scripps Clinic and Research Foundation La Jolla, California	1993 - 1996
Medical Director, Leukapheresis Unit Green Hospital of Scripps Clinic and Research Foundation La Jolla, California	1993 - 1996

Faculty Appointments

Visiting Professor Oncology part time Johns Hopkins School of Medicine	2008-present
Professor of Medicine University of Maryland School of Medicine Baltimore, Maryland	2004 – 2008
Associate Professor of Medicine University of Maryland School of Medicine Baltimore, Maryland	1996 - 2004

Assistant Professor of Medicine
Duke University Medical Center
Durham, North Carolina

1992 - 1993

Associate in Medicine
Duke University Medical Center
Durham, North Carolina

1991 - 1992

LEADERSHIP COMMITTEES

Executive Committee, Johns Hopkins Clinical Research Network
2009-present

Anne Arundel Medical Center

2008-present

Executive Leadership

Pharmacy and Therapeutics

Ambulatory Informatics

Harm Reduction Committee (Chair)

Health Care Disparities (Project leader)

Graduate Medical Education Task force (Chair)

Lab Utilization Oversight Committee

Physicians Enterprise Operations Committee (250 employed physicians)

Physicians Operations Board of Directors

AAMC Board of Trustees Subcommittee on Quality and Patient Safety

Clinical Research Committee Pre-IRB review of Trials)

Summer Student Clinical Research Internship (Chair)

Root Cause Analysis Review Committee

Claims Committee

Johns Hopkins Bayview Medical Center Advisory Board

2010-2012

Johns Hopkins Bayview Medical Center Medical Board
(Clinical Leadership Committee)

2010-2012

RESEARCH ACTIVITIES

Publications

Peer Reviewed Journal Articles

1. **Meisenberg BR**, Robinson WL, Mosley CA, Duke MS, Rabetoy GA, Kosty MP. Thrombotic thrombocytopenic purpura in HIV seropositive males. *Am J Hematol*, 27:212-215, 1988.
2. Crown J, Jakubowski AA, Kemeny N, Gordon M, Gasperetto C, Wong G, Sheridan C, Toner G, **Meisenberg BR**, Botet J. Phase I trial of recombinant human interleukin-1 beta

- alone and in combination with myelosuppressive doses of 5-Fluorouracil in patients with gastrointestinal cancer. *Blood*, 78(6):1420-1427, 1991.
3. **Meisenberg BR**, Davis TA, Monroy RL. Comparison of therapeutic schedules for granulocyte colony stimulating factor administration in non-human primates after high-dose chemotherapy. *Blood*, 79:2267-2262, 1992.
 4. **Meisenberg BR**, Melaragno AJ, Monroy RL. Granulocyte colony stimulating factor for mustard gas induced myelosuppression. *Military Medicine*, 158:470-475, 1993.
 5. **Meisenberg B**. Primary chemotherapy for obstructive jaundice caused by intermediate-grade non-Hodgkin lymphoma. *Cancer*. 1993 Dec 1;72 (11): 3368.
 6. Peters WP, Rosner G, Ross M, Vredenburgh J, **Meisenberg B**, Gilbert C, Kurtzberg J. Comparative effects of G-CFS and GM-CSF on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. *Blood*, 81:1709-1719, 1993.
 7. Peters WP, Ross M, Vredenburgh J, **Meisenberg BR**, Marks LB, Winer E, Kurtzberg J, Bast RC Jr., Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB. High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer. *J Clin Oncol*, 11:1132-1143, 1993.
 8. **Meisenberg BR**, Ross M, Vredenburgh J, Jones R, Shpall EJ, Seigler HF, Coniglio DM, Rosner G, Wu K, Peters WP. A randomized trial of high-dose alkylating agent chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node positive malignant melanoma. *J National Cancer Inst*, 35:1080-1085, 1993.
 9. Gilbert C, **Meisenberg BR**, Vredenburgh J, Ross M, Hussein A, Perfect J, Peters W. Sequential prophylactic oral and empiric once daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. *J Clin Oncol*, 12: 1005-1011, 1994.
 10. Toner GC, Gabrilove JC, Gordon M, Crown M, Jakubowski AA, **Meisenberg BR**, et. al. Phase I-II study of intraperitoneal and intravenous granulocyte-macrophage colony stimulating factor. *J Immunotherapy*, 15(1):59-66, 1994.
 11. Mudar R, Vredenburgh J, Ross M, **Meisenberg BR**, Hussein A, Paulson EK, Peters WP. Hepatic, splenic and renal candidiasis following high-dose chemotherapy and autologous bone marrow transplantation for breast cancer. *Cancer*, 74:1360-1366, 1994.
 12. **Meisenberg BR**. Stage II Breast Cancer - the role of high-dose chemotherapy and autologous stem cell transplant. *Cancer Care*, 2(3):180-184, 1994.
 13. Mudar R, Vredenburgh J, Paulson EK, Ross M, **Meisenberg B**, Hussein A, Peters WP.

- A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. *Cancer*. 1994 Aug 15; 74(4):1360-6.
14. **Meisenberg B**, Lassiter M, Hussein A, Ross M, Vredenburgh JJ, Peters WP. Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. *Bone Marrow Transplant*. 1994 Aug;14(2):287-91.
 15. Nemunaitis J, Ross M, **Meisenberg BR**, et. al. Phase I study of recombinant interleukin 1b (rhil-II 1b) in patient's with bone marrow failure. *Bone Marrow Transplantation*, 14(4):503-588, 1994.
 16. **Meisenberg BR**. Treatment of mustard gas casualties. *Federal Practitioner*, 12:39-44, 1994.
 17. Oktay J, Hamilton N, Knauer CJ, **Meisenberg BR**, Coons HL, Khaleghi T. Case study: CC, a premenopausal 43-year-old woman, found a lump under her arm. *Cancer Pract*. 1994 May-Jun;2(3):180-4.
 18. Hussein AM, Ross M, Vredenburgh, **Meisenberg BR**, et. al. Effects of granulocyte-macrophage colony-stimulating factor produced in chinese hamster ovary cells (regramostim), escherichia coli (molgrastim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. *Eur J Haematol*. 1995 Nov; 55(5):348-56.
 19. **Meisenberg BR**. High-dose chemotherapy with autologous stem cell support for malignant melanoma. *Bone Marrow Transplantation*, 17:903-906, 1996. Review
 20. **Meisenberg BR**, Gollard R, Brehm T, Miller W, McMillan R. Prophylactic antibiotics eliminate bacteremia and facilitate outpatient management after high-dose chemotherapy and autologous stem cell transplantation. *J Supportive Care in Cancer*, 4:364-369, 1996.
 21. **Meisenberg BR**, McKee D, Miller W, McMillan R. P. carinii pneumonia (PCP) following tandem cycles of high-dose chemotherapy and autologous PBPC support. *Bone Marrow Transplantation*, 18:823, 1996.
 22. **Meisenberg BR**, McMillan R, Miller WE. Mobilized peripheral blood progenitor cells support tandem cycles of high-dose chemotherapy. *Bone Marrow Transplantation*, 18:1087-1093, 1996.
 23. **Meisenberg BR**, Miller WE, McMillan R, Callaghan M, Sloan C, Brehm T, Kosty MP, Kroener J, Longmire R, Saven A, Piro LD. Outpatient high-dose chemotherapy with autologous stem cell rescue. *J Clin Oncol*, 15(1):11-17, 1997.
 24. Elkordy M, Crump M, Vredenburgh JJ, Petros WP, Hussein A, Rubin P, Ross M, Gilbert C, Modin C, **Meisenberg B**, Coniglio D, Rabinowitz J, Laughlin M, Kurtzberg J, Peters WP. A Phase I trial of recombinant human interleukin-1b following high-dose

- chemotherapy and autologous bone marrow transplantation. *Bone Marrow Transplantation*, 19(4):315-322, 1997.
25. **Meisenberg BR**, Callaghan M, Sloan C, Sampson, Miller W, McMillan R. Complications associated with central venous catheters inserted for leukapheresis and high-dose chemotherapy and stem cell rescue. *J Supportive Care in Cancer*, 5:223-227, 1997.
 26. Frakes L, Brehm T, Miller W, McMillan R, Kosty M., **Meisenberg BR**. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. *Bone Marrow Transplantation*, 20:473-478, 1997.
 27. **Meisenberg BR**, McMillan R, Miller W. A combination of low-dose cyclophosphamide plus colony stimulating factors is more cost-effective than granulocyte-colony stimulating factor alone to mobilize peripheral blood stem cells. *Transfusion*, 38:209-215, 1998.
 28. **Meisenberg BR**, Ferran K, Hollenbach K, Brehm T, Jollon J, Pior L. Reduced charges and costs associated with outpatient autologous stem cell transplantation. *Bone Marrow Transplantation*, 21:927-932, 1998.
 29. **Meisenberg BR**. Academic oncology and the forces of the marketplace. *Academic Medicine*, 73:833-835, 1998.
 30. **Meisenberg BR**, Brehm T, Sloan C. Preserving quality outcomes during outpatient stem cell transplantation. *Cancer Research and Control*, 7:163-166, 1998.
 31. Tkaczuk KH, Zamboni WC, Tait NS, **Meisenberg BR**, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA. Phase I study of docetaxel and topotecan in patients with solid tumors. *Cancer Chemother Pharmacol*, 46:442-448, 2000.
 32. Zamboni WC, Egorin MJ, Van Echo DA, Day RS, **Meisenberg BR**, Brooks SE, Doyle LA, Nemiboka NN, Dobson JM, Tait NS, Tkaczuk KH. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. *J Clin Oncol*, 18:3288-3294, 2000.
 33. Fassas A, Gojo I, Rapoport A, Cottler-Fox M, **Meisenberg B**, Papadimitriou JC, Tricot G. Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamthasone, etoposide, cisplatin) chemotherapy. *Bone Marrow Transplantation*, 28:399-403, 2001.
 34. Gupta P, **Meisenberg B**, Amin P, Pomeranz HD. Radiation retinopathy: The role of pentoxifylline. *Retina*, 21(5):545-547, 2001.
 35. Fassas AB-T, Buddharaju LN, Rapoport A, Cottler-Fox M, Drachenberg C, **Meisenberg B**, Tricot G. Fatal disseminated adenoviral infection associated with thrombotic

- thrombocytopenic purpura after allogeneic bone marrow transplantation. *Leukemia and Lymphoma*, 42(4):801-804, 2001.
36. Rapoport AP, **Meisenberg B**, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L, Chambers S, McFadden M, Cottler-Fox M, Sarkodee-Adoo C, Chen T, Phillips G, Tricot G. Autotransplantation for advanced lymphoma and hodgkin disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. *Bone Marrow Transplantation*, 29:303-312, 2002.
 37. Knox S, Brooks SE, Wong-You-Cheong J, Ioffe O, **Meisenberg B**, Goldstein DP. Choriocarcinoma and epithelial trophoblastic tumor: Successful treatment of relapse with hysterectomy and high dose chemotherapy with peripheral stem cell support: A Case Report. *Gynecologic Oncology*, 85:204-208, 2002.
 38. Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, Rapoport AP, Cottler-Fox Michele, Tricot G, Ruehle K, **Meisenberg B**. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. *Transfusion Medicine*, 43:78-84, 2003.
 39. Sarkodee-Adoo C, Taran I, Guo C, Buadi F, Murthy R, Cox E, Lopez R, Westphal S, Shope S, O'Connell B, Wethers L, **Meisenberg B**. Influence of preapheresis clinical factors on the efficiency of CD34⁺ cell collection by large-volume apheresis. *Bone Marrow Transplantation*, 31:851-855, 2003.
 40. Rapoport AP, Levine BL, Badros A, **Meisenberg B**, Ruehle K, Nandi A, Rollins S, Natt S, Ratterree B, Westphal S, Mann D, June CH. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. *Bone Marrow Transplantation*, 33:53-60, 2004.
 41. Phillips GL, **Meisenberg BR**, Reece DE, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso DL, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerjee B, Nath R, Rapoport AP, Sarkodee-Adoo C, Takebe N, Vesole DH, Wagner JL, Flomenberg N. Activity of single-agent melphalan 220-300 mg/m² with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. *Bone Marrow Transplant*, 33:781-787, 2004.
 42. Gojo I, Guo C, Sarkodee-Adoo C, **Meisenberg B**, Fassas A, Rapoport AP, Cottler-Fox M, Heyman M, Takebe N, Tricot G. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. *Bone Marrow Transplantation*, 34:69-76, 2004.
 43. Rapoport AP, Guo C, Badros A, Hakimian R, Akpek G, Kiggundu E, **Meisenberg B**, Mannuel H, Takebe N, Fenton R, Bolaños-Meade J, Heyman M, Gojo I, Ruehle K, Natt S, Ratterree B, Withers T, Sarkodee-Adoo C, Phillips GL, Tricot G. Autologous stem cell

transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. *Bone Marrow Transplantation*, 34:883-890, 2004.

44. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, **Meisenberg B**, Tricot G. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. *Clin Cancer Res*, 10(24):8301-8, 2004.
45. Phillips GL, **Meisenberg B**, Reece DE, Adams VR, Badros A, Brunner J, Fenton R, Filicko J, Grosso D, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Nath R, Reed E, Rapoport AP, Takebe N, Vesole DH, Wagner JL, Flomenberg N. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. *Biol Blood Marrow Transplant*, 10(7):473-83, July 2004.
46. Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, **Meisenberg B**, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Phase II study of G3139, a BCL-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. *J Clin Onc*, 23(18):4089-99, 2005.
47. Gojo I, **Meisenberg B**, Guo C, Fassas A, Murthy A, Frenton R, Takebe N, Heyman M, Philips GL, Cottler-Fox M, Sarkodee-Adoo C, Ruehle K, French T, Tan M, Tricot G, Rapoport AP. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. *Bone Marrow Transplantation*, 37(1):65-72, 2006.
48. Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, **Meisenberg B**. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. *Clinical Lymphoma & Myeloma*, 7(3):210-216, Nov 2006.
49. Cheng X, Macvittie T, **Meisenberg B**, Welty E, Farese A, Tadaki D, Takebe N. Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact. *Growth Factors*, 25(3):141-50, June 2007.
50. Lustberg M, Aras O, and **Meisenberg B**. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. *Eur J of Hematology*, 2008 Aug;81(2):154-6
51. Azene EM, Gai QW, Tabar SP, Morrison AL, **Meisenberg B**. Metastasis of a histologically benign-appearing meningioma to the iliac bone. *J Clin Onc*, 2008: 4688-4690.
52. Patel S, Dibase S, **Meisenberg B**, Flannery T, Patel A, Dhople A, Cheston S, Amin P. Phase I Clinical Trial Assessing Temozolomide and Tamoxifen With Concomitant

- Radiotherapy for Treatment of High-Grade Glioma. *Int J Radiat Oncol Biol Phys*. 2012 Feb 1;82(2):739-42.
53. **Meisenberg BR**, Wright RR and Copertino CJB. Reduction in Chemotherapy Order Errors by Computerized Physician Order Entry. *J Oncol Pract*. 2014 Jan1;10(1):e5-9. doi: 10.1200/JOP.2013.000903. Epub 2013 Sep 3
 54. **Meisenberg BR**. Graze, L and Copertino C. Supportive Care Clinic for Cancer Patients Embedded Within an Oncology Practice. *J Community and Support Oncol* 2014 12(6) 205-208.
 55. **Meisenberg Barry**. Balancing Professionalism and Incentives in Health Care Reform. *J of Oncol Pract* 201410(6): 363-364
 56. **Meisenberg, B**, Clemons J, Ness J, Faust N and Clance M. Improving Hospital Performance in the Management of Febrile Neutropenia. *Journal of Supportive Care in Cancer* 2015 23(2): 371-375.
 57. Cattaneo S, Geronimo MCM, Putscher TM, Copertino C and **Meisenberg BR**. Improved Coordination of Care for Patients with Abnormal Chest Imaging: the Rapid Access Chest and Lung Assessment Program. *J Clin. Outcomes Management* 2015 21(10): 453-458

Non-Peer Reviewed Journal Articles

1. Meisenberg BR. Heparin therapy and the PTT. *New Engl J Med*, 316:1162, 1987. (Letter).
2. Toner GC, Jakubowski AA, Crown JP, Meisenberg BR, Sheridan C, Gabrilove J. Colony-stimulating factors and neutrophil migration. *Ann Int Med*, 110:846-847, 1989. (Letter)
3. Meisenberg BR. The silicone controversy--when will science prevail? *New Engl J Med*, 328:733, 1993. (Letter).
4. Peters WP, Ross M, Vredergurg J, Hussein A, Meisenberg BR, Gilbert C, Petros W, Kurtzberg J. Role of cytokines in autologous bone marrow transplantation. *Hematol/Oncol Clin*, 7:734-749, 1993. (Review).
5. Meisenberg BR. High-dose chemotherapy for malignant melanoma. *JNCI*, 85:1961, 1993.
6. Meisenberg BR. Primary chemotherapy for obstructive jaundice caused by intermediate-grade non-hodgkin's lymphoma. *Cancer*, 72:3368, 1993.
7. Meisenberg BR. Etoposide for metastatic breast cancer. *J Clin Onc*, 12:2235, 1994. (Letter).
8. High-dose ifosfamide, carboplatin and etoposide with autologous stem-cell support. B.R. Meisenberg. *J.Clin.Oncol*. 1995:1826-1827 (Letter).
9. Meisenberg BR. High-dose chemotherapy and autologous stem cell rescue for non-hodgkin's lymphoma. *Oncology Case Study Reports*, 1:6-10, 1996.

10. Meisenberg BR, Schmeckel A, Brehm, T, Miller WE, McMillan R. Sequential Cyclophosphamide, GM-CSF and G-CSF to Mobilize Blood Stem Cells. In: Dicke KA and Keating A (Eds). Autologous bone marrow transplantation. 8th International Symposium. University of Texas M.D. Anderson Cancer Center, 561-567, 1997.
11. Meisenberg BR, Miller W, McMillan R. Feasibility and Toxicity of Double Cycles of High-Dose Chemotherapy and Autologous Stem Cell Rescue. Autologous bone marrow transplantation. 8th International Symposium. University of Texas M.D. Anderson Cancer Center, 569-574, 1997.
12. Meisenberg BR. Antiemetic control in patients receiving high-dose chemotherapy and stem cell transplantation. *J Managed Health Care Organizations*, Nov/Dec:11-14, 1997.
13. Meisenberg BR. Who speaks for the patient? Mismatch between ‘emergency contacts’ and ‘health care agents’ in the medical record. Multinational Society for Supportive Care in Cancer Annual Meeting, Miami Florida June 2014
14. Stephen Cattaneo, Barry Meisenberg, Cathy Copertino, Maria Christian Geronimo, Theresa Putscher. The Rapid Access Chest and Lung Assessment Program. *Oncology Issues*. February 2015: 69-73
15. Ley C, Rhule J, Meisenberg B, Ness J, and Arata E. Adoption of the Institute for Healthcare Improvement Global Trigger Tool to Better Identify Harm. Presented by C. Ley at the American Nurses Association Quality Conference, Lake Buena Vista, FL February 2015.
16. Varner A, Meisenberg B Ebner S. Using Research to Drive Practice: Assessing the extent and severity of financial distress among cancer patients and changing the system to address identified needs. Presentation by A Varner at American Association of Oncology Social Worker annual meeting Feb 2015
17. **Meisenberg BR**, Hahn E, Binner M, Weng DE. Factors Associated with Potentially Preventable Oncology Re-admissions. Abstract submitted for annual meeting ASCO 2015
18. **Meisenberg BR**, Ebner S, Ellis EM, Mosley J, Siegrist E, Weng DE, Varner A. Patient Attitudes toward Cancer Care Financial Burden. Abstract submitted for annual meeting ASCO 2015

Extramural Funding

Past Support

Principal Investigator	1997 – 1999
“Oral vs. Intravenous Serotonin Antagonists to Prevent Nausea or Vomiting after High-Dose Chemotherapy and Stem Cell Transplantation”	
SmithKline Beecham	
Total Direct Costs Awarded: \$210,000	

Principal Investigator	1998 – 2000
“Doxorubicin plus Docataxel as ‘Consolidation’ Therapy after High-Dose Chemotherapy and Stem Cell Transplant”	

Rhône-Poulenc Rorer Total Direct Costs Awarded: \$200,000	
Principal Investigator “Myeloid Protein Inhibitory Factor to Prevent Bone Marrow Suppression after Chemotherapy” Human Genome Sciences Total Direct Costs Awarded: \$100,000	1998 – 2002
Principal Investigator “Keratinocyte Growth Factor-2 (KGF-2) in Bone Marrow Transplant Patients at Risk for Developing Mucositis” Human Genome Sciences Total Direct Costs Awarded: \$120,000	2000 – 2002
Principal Investigator “Phase I/II Trial of High-Dose Melphalan with Amifostine Cytoprotection” MedImmune Total Direct Costs Awarded: \$50,000	2000 – 2003
Principal Investigator “G-CSF vs. GM-CSF each with Cyclophosphamide for the Mobilization of Peripheral Blood Stem Cells” Berlex Total Direct Costs Awarded: \$50,000	2001 – 2002
Principal Investigator: STAR “Tamoxifen vs. Raloxifen for the Prevention of Breast Cancer” National Cancer Institute Total Direct Costs Awarded: \$100,000; \$20,000 (2003)	1999 – 2004
Principal Investigator “STI-571 for Newly Diagnosed Patients with Chronic Myelogenous Leukemia” Novartis Total Direct Costs Awarded: \$90,000; \$10,000 (2003)	2000 – 2002
Inter-Agency Personnel Agreement Naval Medical Research Center, Bethesda, MD Salary support plus overhead for role as Director, Combat Injury and Radiation Repair Program	2002 – 2005
Naval Medical Research Center Contract for studies into “Ex-vivo Expansion of Hematopoietic Stem Cells on Human Brain Endothelial Cells Co-Culture” Total Costs: \$2.45 million; Program Director	2003 – 2006

EDUCATIONAL ACTIVITIES

Major Invited Speeches and Presentations

1. Meisenberg BR, *Managed Care and Cancer*, Governor's Task Force on Cancer Control (Annual Meeting), Baltimore, MD, October 1996.
2. Meisenberg BR, *High-Dose Chemotherapy and Stem Cell Transplantation for Breast Cancer and Other Solid Tumors*, Easton Memorial Hospital (Grand Rounds), Easton, MD, March 1997.
3. Meisenberg BR, *The Evolving Role of Stem Cell Transplantation*, National Blue Cross Medical Directors/Case Managers Meeting, Chicago, IL, March 1997.
4. Meisenberg BR, *High-Dose Chemotherapy and Stem Cell Transplantation for Breast Cancer and Other Solid Tumors*, Washington Hospital Center (Grand Rounds), Seattle, Washington, April 1997.
5. Meisenberg BR, *Recent Advances in the Treatment of Ovarian and Lung Cancer*, Conference Chairman, Sheraton Inner Harbor Hotel, Baltimore, MD, June 1997.
6. Meisenberg BR, *High-dose Chemotherapy and Stem Cell Transplantation for Breast Cancer*, Union Memorial Hospital (Keelty Symposium), Baltimore, MD, June 1997.
7. Meisenberg BR, *Prophylactic Antibiotics Eliminate Bacteremia Following High-dose Chemotherapy and Stem Cell Transplantation* International Society of Supportive Care, Toronto, Canada, June 1997.
8. Meisenberg BR, *High-dose Chemotherapy and Stem Cell Transplantation for Breast Cancer and Other Solid Tumors*, St. Agnes Hospital (Grand Rounds), Baltimore, MD, July 1997.
9. Meisenberg BR, *Esophageal Cancer: The Multi-Disciplinary Approach*, University of Maryland Symposium for Community Physicians, Baltimore, MD, July 1997.
10. Meisenberg BR, *Managed Care in Other Markets*, Managed Care Symposium for UMMS Chief Residents, Baltimore, MD, October 1997.
11. Meisenberg BR, *High-dose Chemotherapy in the Outpatient Setting: Reduced Costs and Charges* International Society of Supportive Care, Luxembourg, November 1997.
12. Meisenberg BR, *New Treatment Options for Patients with Advanced Breast Cancer*, American Cancer Society Regional Meeting, Salisbury, MD, November 1997.
13. Meisenberg BR, *High-dose Chemotherapy and Stem Cell Transplantation for Breast Cancer and Other Solid Tumors*, University of Maryland Medical Center (Hematology/Oncology Grand Rounds), Baltimore, MD, December 1997.
14. Meisenberg BR, *High-dose Chemotherapy and Stem Cell Transplantation for Breast Cancer and other Solid Tumors*, Cumberland General Hospital (Grand Rounds), Cumberland, MD, May 1998.

15. Meisenberg BR, *Tamoxifen for the Prevention of Breast Cancer: Time to Act?*, American Cancer Society Regional Meeting., November 1998.
16. Meisenberg BR, *Outpatient Bone Marrow Transplantation*, Symposium Chair, American Society for Blood and Marrow Transplantation/International Bone Marrow Transplantation Registry Joint Meeting, Keystone, Colorado, March 1999.
17. Meisenberg BR, *Potential for Stem Cell Transplantation after Radiation Injury*, Medical Effects of Ionizing Radiation Conference, Armed Forces Radiobiology Institute, Bethesda, MD, March 2000.
18. Meisenberg BR, *Growth Factors for the Treatment of Radiation Casualties*, Medical Effects of Ionizing Radiation Conference, Armed Forces Radiobiology Institute, Bethesda, MD, March 2000.
19. Meisenberg BR, *Tamoxifen for the Prevention of Breast Cancer: Controversy at Every Turn*, University of Maryland, Department of Medicine (Grand Rounds), Baltimore, MD, November 2000.
20. Meisenberg BR, Conference Co-Chair, Annual Meeting of Multinational Society for Supportive Care in Cancer, Washington, D.C., March 2000.
21. Meisenberg BR, Conference Chair, *Multidisciplinary Oncology: The Year 2000 and Beyond*, University of Maryland Greenebaum Cancer Center, Baltimore, MD, September 2000.
22. Meisenberg BR, Conference Chair, *Advances in Oncology: An Update for Case Managers*, University of Maryland Greenebaum Cancer Center, Baltimore, MD, March 2001.
23. Meisenberg BR, *Advances in Signal Transduction Inhibitors*, University of Maryland Greenebaum Cancer Center, Baltimore, MD, January 2002.
24. Meisenberg BR, *Genomics in Oncology*, pre-ASCO 2002 Symposium, American Society of Clinical Oncology, Orlando, Florida, May 2002.
25. Meisenberg BR, *Infections after Bone Marrow Transplantation*, 6th International Conference on Cancer Care, American-Russian Cancer Alliance, Moscow, Russia, November 2003.
26. Meisenberg BR, *Cytokines as an Adjuvant in the Treatment of Immune-Compromised Patients*, 6th International Conference on Cancer Care, American-Russian Cancer Alliance, Moscow, Russia, November 2003.
27. Meisenberg BR, *Prevention of Nausea and Vomiting after Chemotherapy*, 6th International Conference on Cancer Care, American-Russian Cancer Alliance, Moscow, Russia, November 2003.
28. Meisenberg BR, Visiting Professor, N.N. Blokhin Russian Cancer Research Agency, Moscow, Russia, Sponsor: American-Russian Cancer Alliance, November 2003.
29. Meisenberg BR, Symposium on Cancer Care for Primary Care Physicians: conference organizer. Topic: *Oncology care in a Shifting Medical Landscape*. October, 2009.

30. Meisenberg BR. Symposium on Cancer Care for Primary Care Physicians. Conference Organizer. Topic: *Cancer survivorship: a Challenge for Patients, Oncologists and Primary Care Physicians*. Annapolis, MD. October, 2010
31. Meisenberg BR . Symposium on Hematology and Oncology for Primary Care Physicians. Annapolis MD. *Cancer Screening: a “simple” concept made complicated*. November 2012
32. Meisenberg BR. Family Medicine Department Grand Rounds. Anne Arundel Medical Center, Annapolis MD *PSA testing: more harm than good?* February 2013
33. Meisenberg BR. Academy Health Research Symposium: Transforming Health and Healthcare: Focus on Maryland. Baltimore MD June 2013 *Reducing Costs by Improving Quality*
34. Meisenberg BR Anne Arundel County Conquer Cancer Task Force Annapolis MD September 2013 *Cancer Survivorship and Rehabilitation*
35. Meisenberg BR Anne Arundel County Conquer Cancer Task Force Annapolis MD February 2014 *How to talk to the Public about Waste and Value in Cancer Care*
36. Meisenberg BR. Improving Hospital performance in the management of Febrile Neutropenia. June 2014 *Johns Hopkins Medicine Patient Safety Summit*. June 2014
37. Meisenberg BR. Febrile Neutropenia. *Multinational Society for Supportive Care in Cancer Annual Meeting*, Miami Florida June 2014

Book Chapters

1. Peters W, Ross M, Vredenburgh J, Wu K, Winer E, Meisenberg BR, Hussein A. *High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer*. In: Salmon SE, (Ed.), *Adjuvant Therapy of Cancer VII*. Philadelphia: J.B.Lippincott Co., 207-213, 1993.
2. Peters WP, Ross M, Vredenburgh J, Wu K, Rosner G, Winer E, Meisenberg BR, Hussein A. *High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer*. In: Salmon SE, (Ed.), *Adjuvant Therapy of Cancer VII*. Philadelphia: J.B.Lippincott Co., 271-277, 1993.
3. Meisenberg BR. *Non-hodgkin’s lymphoma*. In: Rakel RE, (Ed.), *Manual of Medical Practice*. Philadelphia: Saunders, 367-369, 1995.
4. Meisenberg B, and Yarlagadda L. *Pineal region tumors: chemotherapy perspective*. In: Chin L and Regine W, (Eds.), *Principles and Practice of Stereotactic Radiosurgery*. New York: Springer, 377-382, 2008.

Letters

1. Meisenberg BR. Post remission therapy for acute myelogenous leukemia. *New Engl J Med*, 332:1718, 1995.
2. Meisenberg BR. High-dose ICE for malignant diseases. *J Clin Oncol*, 13:1826, 1995.

3. Meisenberg BR. Which non-hodgkin's lymphoma patients benefit from autologous bone marrow transplantation? *Oncology News International*, 5:34, 1996.
4. Meisenberg BR. Should Physicians Consider Costs

Teaching

Grand Rounds University Department of Medicine	Feb 2008
"The Physician and the Pharmaceutical Industry"	
Grand Rounds, University of Maryland Department of Medicine	Spring 1997
"Approach to Breast Cancer"	1997
Medical Residents; 1 hour every other month	
Graduate Student Course	Fall 1998
"Biology of Cancer: Graft vs. Host Disease"	
Course in Emergencies, "Hematology-Oncology Emergencies"	1998, 1999
2 nd Year Medical Students; 1 hour	
P & T Course, "Hematologic Malignancies" (annually)	2000 - 2006
- Develop and deliver 3 core lectures for 2 nd Year Students	
(3 lecture hours plus 10 hours of prep time; 120 students)	
- Develop and monitor 2 small group sessions	
(1 hour; 60 students each)	
Program in Medical technology lecturer: Bone marrow Transplantation" and	
"Hematologic Malignancies"	2004-2008

Teaching Rounds

(Location of service and number of months vary by year – average is 4-6 months/year)

University of Maryland Greenebaum Cancer Center Service, Medical Residents, Oncology Fellows:	
Leukemia and Solid Tumor Service Attending	1996 - 2008
7 days/week, 3-5 hours/day, 2-4 weeks/year; 2 residents monthly	
Stem Cell Transplant Unit Service Attending	1996 - 2008
7 days/week, 4 hours/day; 1 fellow, pharmacy students	
Weekend call: 8-12 weekends/year, 6 hours per weekend; 1 fellow	
Hematology Consult Service	1996 – 2008
1 month/year, 7 days/week, 2-4 hours/day; 1 fellow, 1 medical resident	
Medical Oncology Consult Service	1996 – 2008
1-2 hours/day, 1month/year; 1 fellow, 1 resident	

Fellows Core Lectures

Approximately 1 of the following lectures every 1-2 months, 1 hour each; 6 fellows, 3-4 medical residents

“Bone Marrow Transplant for Solid Tumors”
“Approach to Lymphomas”
“Use of Cytokines”
“Antiemetic Therapy with Anti-neoplastic Therapy”
“The Pharmaceutical Industry and Academic Medicine”

Mentoring (Annually)

1st year Medical Residents 1998 – 2004

CLINICAL ACTIVITIES

Certifications

Diplomat, National Board of Medical Examiners, #109678	1983
Diplomat, American Board of Internal Medicine, #109678	1986
Diplomat, American Board of Internal Medicine (Hematology), #109678	1988
Diplomat, American Board of Internal Medicine (Oncology), #109678	1989

Medical Licensures

State of North Carolina, #R-0022011	1991 - 2001
State of California, #G-077164	1993 - 1996
State of Maryland, #D-51260	1996 - present

ORGANIZATIONAL ACTIVITIES

Editorial Activities

Reviewer (AD Hoc) <i>Journal of Clinical Oncology</i> <i>Cancer Investigation</i> <i>Blood</i> <i>Bone Marrow Transplantation</i> <i>Supportive Care in Cancer</i> <i>Journal of Oncology (Contributing Editor)</i>	1997 - 2002
---	-------------

Professional Societies

Elected Fellow, American College of Physicians
American Society of Clinical Oncology
American Society of Hematology
American Society for Blood and Marrow Transplantation
International Society for Hematotherapy and Graft Engineering
International Society for Supportive Care in Cancer
International Society for Experimental Hematology
Maryland Society of Clinical Oncology

RECOGNITION

Honors and Awards

National Merit Finalist	1974
New York State Regents Scholar	1974
Summa Cum Laude, Biochemistry, State Univ. of New York at Stony Brook	1978
Phi Beta Kappa	1978
Aequanimitis Award (Outstanding Internal Medicine Resident), Naval Hospital	1986
Mildred Mindell Foundation Award: Outstanding Physician with commendation by the Mayor of Baltimore, for excellence in patient care.	2006
Cancer Center Director's Award for enhancements in Patient safety	2006
Council of Ambulatory Medical Director's Award for Quality Improvement Efforts	2007

Military Awards

Navy Achievement Medal	1984
Defense Ribbon	1991
Navy Commendation Medal	1991
Navy Reserve Medal	1994

OTHER PROFESSIONAL ACCOMPLISHMENTS

Military Service

Medical Officer Naval Mobile Construction Battalion 62 Gulfport, Mississippi	1982 - 1984
Principal Investigator, CALGB-Affiliate Naval Hospital San Diego, California	1989 - 1991
Staff Physician, Hematology/Oncology Naval Hospital San Diego, California	1989 - 1991
Temporary duty at Naval Medical Research Command in support of Operation Desert Shield. Developed research project on use of hematopoietic growth factors in the treatment of mustard gas casualties. Principal investigator and author of unique Navy IND application, approved by the FDA for the use of investigational G-CSF following exposure of DOD personnel to high-dose mustard gas.	September 1990 - December 1990
Temporary duty as Consulting Hematologist in Landstuhl, Germany in support of Operation Desert Storm	January 1991 - March 1991
Commander U.S. Naval Reserve	1991 - 1999

Captain
U.S. Naval Reserve

1999 – 2006

Major Research Interests

Patient Safety
Outcomes Analysis
Implementation of Electronic Health Records
High-Dose Chemotherapy with Stem Cell Rescue
Cytokines/Growth Factors
Bone Marrow Protecting Agents
Anti-emetic Therapy
Ex-Vivo Hematopoietic Stem Cell Expansion

Other Institutional Service

Chair, Clinical Research Committee, Univ. of MD Greenebaum Cancer Center	1997 - 2002
Alternate Faculty Senate	1997 - 2002
Search Committee Pediatric Hematology Oncology Division Head	2000
Search Committee Pulmonary Division Head	2000 - 2001
Clinical Service Standards Comm.; Janine Good, M.D., Chair	2000 - 2008
Hospital Pharmacy and Therapeutics Committee; Frank Calia, M.D., Chair	2000 - 2005
School of Medicine Ad hoc Committee on defining standards of care; E. Francois Aldrich, M.D., Chair	2001 - 2002
Data and Safety Monitoring Committee, Univ. of MD Greenebaum Cancer Center	2002 - 2008
UMMC Pharmacy Supervisory Committee	2002 - 2008
UMMC chemotherapy (subcommittee of P and T) , Chair	2005 - 2008
Performance Improvement Steering Committee UMMC	2006 - 2008
University of Maryland School of Medicine Compliance Committee	2006 - 2008
Interviewer, University of Maryland School of Medicine	2006 - 2007
Hazardous Drug Policy Committee	2007 - 2008

State and Local Service

State Legislature Advisory Committee: Clinical Trials Reimbursements Policy	1997-1998
County Task Force, “ <i>Conquering Cancer in Anne Arundel County</i> ”	Oct. 2000-2001, 2003

Regional/National Service

Medical Advisory Board, Transplant Network Services	1993 - 1995
Oncology Advisory Board, Health Net Managed Care Network	1993 - 1996
Green Cancer Center Scientific Review Committee	1993 - 1996
Green Hospital Committee for the Protection of Human Subjects	1993 - 1996
Medical Advisory Board of Women’s Cancer Task Force	1993 - 2000
Oncology Advisory Board, MDIPA	1996 - 2000
Medical Advisory Board, Blue Cross/Blue Shield of Maryland	1997 - 2000
Bone Marrow Transplant Quality Committee, National Blue Cross Blue Shield	1997 - 2003
Briefing for Senior Military Health Care Leadership, “ <i>Strategies for Treatment of Radiation Emergencies</i> ”	September 2002
Briefing for Congressional Staff, “ <i>Radiation Injury and the Role of Stem Cell Transplantation</i> ”	January 2003
Briefing for Congressional Staff, “ <i>Non-Embryonic Bone Marrow Stem Cells</i> ”	October 2003

for Tissue Repair”

Navy Representative Joint Technology Coordinating Group Seven:
Radiation Health Effects

2004- 2006

Bureau of Medicine and Surgery, Department of the Navy, Washington, D.C.